[
  {
    "ts": "2026-02-07T08:06:02+00:00",
    "headline": "Why Analysts See Boston Scientific (BSX) Differently After Target Cuts And A Fair Value Reset",
    "summary": "The fair value estimate for Boston Scientific has been reset from US$125.45 to US$108.66, while the modeled discount rate is essentially steady at 7.87% and revenue growth expectations move from 11.18% to a more conservative 10.74%. This shift lines up with recent Street research, where many firms are trimming targets and treating earlier valuation levels as too rich, even as some still describe the stock as a preferred large cap MedTech name or a top idea alongside a select peer group. As...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-boston-scientific-080602044.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2280586a-7b66-35ab-9175-215b7b00d9c3",
      "content": {
        "id": "2280586a-7b66-35ab-9175-215b7b00d9c3",
        "contentType": "STORY",
        "title": "Why Analysts See Boston Scientific (BSX) Differently After Target Cuts And A Fair Value Reset",
        "description": "",
        "summary": "The fair value estimate for Boston Scientific has been reset from US$125.45 to US$108.66, while the modeled discount rate is essentially steady at 7.87% and revenue growth expectations move from 11.18% to a more conservative 10.74%. This shift lines up with recent Street research, where many firms are trimming targets and treating earlier valuation levels as too rich, even as some still describe the stock as a preferred large cap MedTech name or a top idea alongside a select peer group. As...",
        "pubDate": "2026-02-07T08:06:02Z",
        "displayTime": "2026-02-07T08:06:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFax.1EIpS7VVYvaDN0jRw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OB69YGFZw788CGHTsahrkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f07ef6f3ab742340c5e8f39cd1ee19ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-boston-scientific-080602044.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-boston-scientific-080602044.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]